Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT04313153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04313153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
Lead sponsor
Akebia Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
May 27, 2020
Completion date
June 22, 2022
Enrollment
319 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

anemia